#HER2 Positive Gastric Cancer Market
Text
The Rise of Tech-Driven Therapies: Reshaping the Global HER2 Positive Gastric Cancer Market
The global HER2-positive gastric cancer treatments market is expected to grow at a compound annual growth rate (CAGR) of 3.5%, with a current valuation of US$ 1261.8 million by 2023. Healthcare technology advancements are expected to drive the market to US$1779.8 million by 2033.
The market for gastric cancer that is HER2-positive will likely experience rapid expansion as more people become aware of the symptoms and causes of the illness.The market is expected to develop due to an increase in product releases and approvals, as well as increased business activity in conducting clinical trials to find effective treatments for patients with stomach cancer that is HER2 positive.
For instance, in January 2021, the U.S. FDA approved Enhertu, an antibody-drug conjugate product, to treat HER-2 positive stomach cancers that have spread. Additionally, it is projected that the market’s growth would be aided by the increasing number of drugs in the pipeline that are gaining special designations.
Reveal Patterns With Your Sample Report Preview:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16232
North America dominates the HER 2 positive gastric cancer market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.
Key Takeaways from the Market Study
As of 2023, the HER2 positive gastric cancer market was valued at US$ 1261.8 Million
From 2023 to 2033, the HER2 positive gastric cancer industry is poised to grow at an 3.5% CAGR
By 2033, the HER2 positive gastric cancer market is slated to reach a valuation of US$ 1779.8Million
Based on therapy, the targeted therapy segment dominated the global market in 2023 with a revenue share of over 55.4%.
China is poised to yield a CAGR of 3.2% with respect HER2 positive gastric cancer in 2033
“Technological advancement in healthcare and increase in the prevalence of gastric cancer is expected to radically transform the HER 2 positive gastric cancer market in the coming years,” comments an analyst at FMI.
Competitive Landscape
AstraZeneca
Bayer
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd
Hutchison Medipharma
LintonPharm
Shanghai Henlius Biotech
Sanofi
Pfizer
Novartis AG
Manufacturers and players functional in the global HER 2 positive gastric cancer market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.
In September 2022 -Shanghai Henlius Biotech, Inc announced a phase 1 clinical trial of the company’s HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanised monoclonal antibody(mAb) injection, has been completed in patients with HER2 overexpressing advanced solid tumours. The results of this study demonstrated the good safety and tolerability of HLX22.
In January 2022 — LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that it has completed the enrollment of stage 1 of the global phase III trial (clinicaltrials.gov: NCT04222114). This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis (GCPC).
Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey
HER2 Positive Gastric Cancer Market by Therapy:
Chemotherapy
Immunotherapy
Radiation Therapy
Targeted Therapy
HER2 Positive Gastric Cancer Market by Stage:
Stage I
Stage II
Stage III
Stage IV
HER2 Positive Gastric Cancer Market by End-User:
Ambulatory surgery centres,
Hospitals and Specialty clinics
Others
0 notes
Text
HER2-Positive Gastric Cancer Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Pfizer, Hanmi Pharma, Bristol-Myers Squibb, Merck Sharp & Dohme
http://dlvr.it/T5HRsq
0 notes
Text
HER2-Positive Gastric Cancer Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Pfizer, Hanmi Pharma, Bristol-Myers Squibb, Merck Sharp & Dohme
http://dlvr.it/T5HB2f
0 notes
Text
HER2+ Positive Gastric Cancer Market - Markets and Data
Global HER2+ gastric cancer market is projected to witness a CAGR of 3.37% during the forecast period 2024-2031, growing from USD 1304.5 million in 2023 to USD 1700.59 million in 2031. Globally, gastric cancer ranks third in terms of cancer-related deaths and is the sixth most frequent type of cancer. Although there are no symptoms associated with early stomach cancer, some people receive confirmation about the cancer once they are diagnosed.
0 notes
Text
HER2-Positive Gastric Cancer Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Pfizer, Hanmi Pharma, Bristol-Myers Squibb, Shanghai JMT-Bio Inca
http://dlvr.it/Swv0Cs
0 notes
Text
Using its unique expanded genetic code technology platform, Ambrx Biopharma Inc.(AMAM stock) , a clinical-stage biologics firm, discovers and creates tailored precision biologics. Its lead product candidate, ARX788, is an anti-HER2-drug conjugate (ADC) that is being studied in numerous clinical trials to treat of breast cancer, stomach junction cancer, as well as other solid tumors. These trials, which are currently in Phase 2 and Phase 3, are also being conducted for the treatment of gastric and breast cancers that have metastasized and are HER2-positive.
The company is also working on two earlier-stage product candidates: ARX305, an anti-CD70 ADC in investigational new chemical studies for the treatment of kidney cell carcinoma and other cancers. And ARX517, an anti-PSMA ADC in a Phase 1 clinical trial for the therapy of prostate cancer and other tumors.
It is also creating additional multiple product candidates with an eye toward immuno-oncology applications, such as ARX102, an immuno-oncology IL-2 path agonist that targets and gamma receptors on cytotoxic T cells to activate the patient's own immune system, and ARX822, a fab-small macromolecular bispecific that is used in preclinical phase for cancers. Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health are all partners of Ambrx Biopharma Inc. The business was founded in 2003, and its main office is in La Jolla, California.
Who Are The Major Owners Of AMAM Stock?
17 investment banks and fund managers owned AMAM stock in Ambrx Biopharma over the previous two years. Fosun International Ltd ($37.88M), Adage Capital Partners GP L.L.C. ($17.37M), BlackRock Inc. ($11.75M), FMR LLC ($10.22M), Octagon Capital Advisors LP ($8.82M), Suvretta Capital Management LLC ($6.15M), and Millennium Management LLC ($2.82M) were the institutional investors with the largest investments.
AMAM stock is held by institutions 44.21% of the time. In the past 24 months, institutional investors have purchased 9,197,182 shares altogether. This volume of purchases entails about $158.86M in transactions.
In the past 24 months, investment banks have sold 274,909 shares in total. This share sale volume equates to roughly $1.55M in business. Institutional shareholders Cormorant Asset Management LP ($0.15M), BlackRock Inc. ($48.46K), Tudor Investment Corp Et Al ($39.86K), Ghisallo Capital Management LLC ($25K), and Renaissance Technologies LLC ($11.60K) all sold shares of Ambrx Biopharma in the past 24 months.
Short Sellers Of Ambrx Biopharma?
November saw a decrease in short interest in Ambrx Biopharma. 3,800 shares totaled short interest as of November 15th, which is a decrease of 20.8% from the 4,800 share total as of October 31st. The days-to-cover ratio is currently 0.1 days based on an average daily trading volume of 30,600 shares.
Short sales of the company's shares make up about 0.0% of the total. Any online trading account can be used to buy shares of AMAM stock. WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab are a few well-known online brokerages providing access to the American stock market.
Competitors Of AMAM
The top rivals of Ambrx Biopharma include Elevation Oncology (ELEV), Cortexyme, Idera Pharmaceuticals (IDRA), Rubius Therapeutics (RUBY), Jasper Therapeutics (JSPR), Entera Bio (ENTX), AIM ImmunoTech (AIM), ERYTECH Pharma (ERYP), Genetic Technologies (GENE), Surrozen (SRZN), and (CRTX).
All of these businesses fall under the "medical" category. Ambrx Biopharma is not as well-liked by analysts as other Medical companies. AMAM stock has a consensus rating of Moderate Buy, whereas the typical consensus rating for healthcare firms is Buy.
Ambrx Biopharma is disliked by customers more than other Medical businesses. Ambrx Biopharma had an outperform vote from 52.38% of people, versus an average of 66.26% for medical firms.
Entera Bio And Ambrx Biopha
rma?
Compared to Ambrx Biopharma, Entera Bio has smaller revenue but larger earnings. Shares in Ambrx Biopharma are held by institutions 44.2% of the time. Comparatively, institutional investors own 17.1% of the shares in Entera Bio. Shares of Ambrx Biopharma are held by company insiders to a 5.1% stake. Comparatively, insiders own 5.2% of the shares in Entera Bio. Solid organizational ownership is a sign that endowments, hedge funds, and big money managers are betting on a company's long-term ability to outperform the market.
Compared to Entera Bio's profit income of -1,796.49%, Ambrx Biopharma has a net margin of 0.00%. Entera Bio's return on equity was beaten by Ambrx Biopharma's equity return of 0.00%. When compared by users, Entera Bio earned 157 more votes for outperformance than Ambrx Biopharma. Similarly, while just 52.38% of people gave Ambrx Biopharma an outstanding vote, 66.14% of users awarded Entera Bio an outperform rating.
With a beta of 1.34, AMAM stock price is 34% less volatile than that of the S&P 500. Compared to the S&P 500, Entera Bio's share price is 84% more unpredictable with a beta of 1.84. Ambrx Biopharma received 48 more media mentions than Entera Bio in the past week. Ambrx Biopharma received 49 mentions according to us, while Entera Bio received just one.
Shares Of Ambrx Rise After Promoting Early Safety
Preliminary safety and effectiveness findings from the Phase 2 ACE-Breast-03 study were released by Ambrx Biopharma Inc. (NASDAQ: AMAM), which encouraged early safety data from the breast cancer candidate.
In patients with HER2-positive mBC who are resistant or refractory to T-DM1, the data showed a 51.7% overall response rate (ORR) and a 100% disease control rate (DCR) after therapy with ARX788. Patients received therapy for a median of 7.2 months, as treatment is still ongoing.
In China, Amrbrx's partner NovoCodex Biopharmaceuticals is currently conducting two Phase 3 trials so one registration-enabled Phase 2 study with ARX788, with readouts expected in 2023. The last check Friday's premarket session saw AMAM shares up 180.6% to $1.15.
How Simple Is It For Ambrx Biopharma To Raise Money?
Many people may be thinking that Ambrx Biopharma has to raise more money in the future because its income is falling and its operating cash flow is rising. Companies have the option of raising capital through debt or equity.
Publicly traded corporations benefit greatly from the ability to sell investors shares in order to raise capital and finance expansion. By comparing a company's cash burn to its market capitalization, we may determine how much investors would be affected if the business had to issue capital to pay for the cash burn for an additional year.
Ambrx Biopharma seems to have a market value of $20 million and spent $7 million last year, or 350% of its market value. We believe there is a substantial risk of financial hardship given how big that expenditure is in comparison to the company's market value, and we would be extremely cautious about keeping the AMAM stock.
What Are The Average Rating And Price Objective For Ambrx Biopharma?
Based on the current 1 controlled transaction and 1 buy rating for AMAM, the consensus opinion for AMAM stock is Moderate Buy, according to the 2 analysts who have issued ratings in the past year. Ambrx Biopharma's average 12-month price objective is $4.00, with a premium price target of $4.00 and a low cost target of $4.00.
According to two Wall Street experts who have predicted the price of AMAM for the next year, the average price target is $11.00, with the maximum prediction for the company being $16.00 and the lowest prediction being $6.00.
By April 2023, according to the majority of Wall Street analysts, the share price of Ambrx Biopharma might be $11.00.
Is AMAM A Successful Business?
The cash burn for AMAM is $70163000. It has at least a year's worth of coverage in the form of cash and short-term investments. AMAM has cash and short-term investments of
$111.72 million. This is sufficient to fund its $70.16M yearly cash burn.
AMAM has a small 0.28 debt to equity ratio. On the balance sheet of AMAM, short-term assets outnumber long-term liabilities. On the balance sheet of AMAM, short-term assets exceed short-term liabilities. Cons: Over the past year, AMAM's profit margin has decreased from 325.6% to 1.729.9%.
According to our examination of Ambrx Biopharma's cash position, its cash runway was comforting, but the ratio of its cash burn to market value has us a little concerned. We have very little faith in the company's capacity to control its cash burn after taking all the data stated in this article into account, and we predict it will need additional money.
The Basics Of Ambrx Biopharma
The value of AMAM stock is 43, which is higher than the average for the Biotechnology sector. Currently, 3 out of 7 due diligence tasks are being passed by AMAM. AMAM's Financials rating is 0, which is the same as the industry average for the Biotechnology sector.
AMAM stock is presently failing 0 of 7 checks for due diligence. The AMAM stock forecast score is 0, which is the same as the sector average for biotechnology. AMAM stock is presently failing 0 of 9 checks for due diligence.
The Performance score for AMAM stock is 71, which is higher than the industry average for biotechnology. Five out of ten due diligence checks are passing for AMAM. We disregard this dimension because Ambrx Biopharma has little or no historical dividend history.
Recommendations Most Recent From AMAM Analysts
On May 24, 2022, a Goldman Sachs analyst decreases their price objective for AMAM stock from $6 to $4 while maintaining a hold rating.
On April 7, 2022, Joel Beatty, a high 17% analyst from Baird, commences covering on AMAM with a buy recommendation and publishes their $16.00 price target.
On February 28, 2022, Corinne Jenkins of Goldman Sachs, a top 48% analyst, announces the beginning of covering on AMAM with such a hold recommendation and a $6.00 price target.
In 2022, Should I Buy Or Sell Ambrx Biopharma Stock?
In the past year, Ambrx Biopharma has received "buy," "hold," and "sell" evaluations from 2 Wall Street research analysts. For the stock, there is presently 1 hold rating and 1 buy rating. Wall Street research experts generally agree that investors should "buy" AMAM stock. On Friday, June 18th 2021, (AMAM) raised $126 million through an initial public offering.
At a price of $17.00–$19.00 per share, the corporation issued 7,000,000 shares. The underwriters for the initial public offering were Goldman Sachs, BofA Securities, and Cowen. The time it would take for a corporation to exhaust its cash on hand at its current cash burn rate is known as its cash runway. Ambrx Biopharma had 111 million dollars in cash and no debt as of June 2022.
Looking back at the previous year, the business spent $70 million. So, starting in June 2022, AMAM stock forecast had a financial runway of about 19 months. This is not too bad, and unless cash burn substantially decreases, it is safe to assume the financial runway is coming to an end.
Ambrx Biopharma Stock Forecast 2022
While it is not anticipated that AMAM stock forecast annual earnings rate of growth of N/A will surpass the statistically important earnings growth rate of 9.29% for the US biotechnology industry, neither is it anticipated to surpass the average AMAM stock forecast earnings rate of growth of 70.08% for the US market.
The revenue for AMAM stock forecast in 2022 is -$90,558,000. One Wall Street analyst predicted that AMAM stock forecast earnings would be -$75,691,975 on average in 2022, with the highest AMAM earnings prediction being -$75,691,975 and the top AMAM stock forecast being -$75,691,975.
The current Earnings Per Share (EPS) for Ambrx Biopharma is $6.72. Analysts expect AMAM stock forecast EPS to be -$0.28 on average for 2022, with the lowest and highest estimates both coming in at -$0.28.
Ambrx Biopharma Stock Forecast
2023
AMAM stock forecast is anticipated to make -$67,582,121 in 2023, with the smallest earnings estimate being -$67,582,121 and the actual figure being -$67,582,121. By April 7, 2023, analysts on Wall Street believe the share price of Ambrx Biopharma might reach $11.00.
From the present share price of $4.54 for AMAM, the average AMAM stock forecast predicts a possible increase of 142.29%. AMAM stock forecast EPS is anticipated to be negative $0.25 in 2023.
0 notes
Text
Using its unique expanded genetic code technology platform, Ambrx Biopharma Inc.(AMAM stock) , a clinical-stage biologics firm, discovers and creates tailored precision biologics. Its lead product candidate, ARX788, is an anti-HER2-drug conjugate (ADC) that is being studied in numerous clinical trials to treat of breast cancer, stomach junction cancer, as well as other solid tumors. These trials, which are currently in Phase 2 and Phase 3, are also being conducted for the treatment of gastric and breast cancers that have metastasized and are HER2-positive.
The company is also working on two earlier-stage product candidates: ARX305, an anti-CD70 ADC in investigational new chemical studies for the treatment of kidney cell carcinoma and other cancers. And ARX517, an anti-PSMA ADC in a Phase 1 clinical trial for the therapy of prostate cancer and other tumors.
It is also creating additional multiple product candidates with an eye toward immuno-oncology applications, such as ARX102, an immuno-oncology IL-2 path agonist that targets and gamma receptors on cytotoxic T cells to activate the patient's own immune system, and ARX822, a fab-small macromolecular bispecific that is used in preclinical phase for cancers. Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health are all partners of Ambrx Biopharma Inc. The business was founded in 2003, and its main office is in La Jolla, California.
Who Are The Major Owners Of AMAM Stock?
17 investment banks and fund managers owned AMAM stock in Ambrx Biopharma over the previous two years. Fosun International Ltd ($37.88M), Adage Capital Partners GP L.L.C. ($17.37M), BlackRock Inc. ($11.75M), FMR LLC ($10.22M), Octagon Capital Advisors LP ($8.82M), Suvretta Capital Management LLC ($6.15M), and Millennium Management LLC ($2.82M) were the institutional investors with the largest investments.
AMAM stock is held by institutions 44.21% of the time. In the past 24 months, institutional investors have purchased 9,197,182 shares altogether. This volume of purchases entails about $158.86M in transactions.
In the past 24 months, investment banks have sold 274,909 shares in total. This share sale volume equates to roughly $1.55M in business. Institutional shareholders Cormorant Asset Management LP ($0.15M), BlackRock Inc. ($48.46K), Tudor Investment Corp Et Al ($39.86K), Ghisallo Capital Management LLC ($25K), and Renaissance Technologies LLC ($11.60K) all sold shares of Ambrx Biopharma in the past 24 months.
Short Sellers Of Ambrx Biopharma?
November saw a decrease in short interest in Ambrx Biopharma. 3,800 shares totaled short interest as of November 15th, which is a decrease of 20.8% from the 4,800 share total as of October 31st. The days-to-cover ratio is currently 0.1 days based on an average daily trading volume of 30,600 shares.
Short sales of the company's shares make up about 0.0% of the total. Any online trading account can be used to buy shares of AMAM stock. WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab are a few well-known online brokerages providing access to the American stock market.
Competitors Of AMAM
The top rivals of Ambrx Biopharma include Elevation Oncology (ELEV), Cortexyme, Idera Pharmaceuticals (IDRA), Rubius Therapeutics (RUBY), Jasper Therapeutics (JSPR), Entera Bio (ENTX), AIM ImmunoTech (AIM), ERYTECH Pharma (ERYP), Genetic Technologies (GENE), Surrozen (SRZN), and (CRTX).
All of these businesses fall under the "medical" category. Ambrx Biopharma is not as well-liked by analysts as other Medical companies. AMAM stock has a consensus rating of Moderate Buy, whereas the typical consensus rating for healthcare firms is Buy.
Ambrx Biopharma is disliked by customers more than other Medical businesses. Ambrx Biopharma had an outperform vote from 52.38% of people, versus an average of 66.26% for medical firms.
Entera Bio And Ambrx Biopha
rma?
Compared to Ambrx Biopharma, Entera Bio has smaller revenue but larger earnings. Shares in Ambrx Biopharma are held by institutions 44.2% of the time. Comparatively, institutional investors own 17.1% of the shares in Entera Bio. Shares of Ambrx Biopharma are held by company insiders to a 5.1% stake. Comparatively, insiders own 5.2% of the shares in Entera Bio. Solid organizational ownership is a sign that endowments, hedge funds, and big money managers are betting on a company's long-term ability to outperform the market.
Compared to Entera Bio's profit income of -1,796.49%, Ambrx Biopharma has a net margin of 0.00%. Entera Bio's return on equity was beaten by Ambrx Biopharma's equity return of 0.00%. When compared by users, Entera Bio earned 157 more votes for outperformance than Ambrx Biopharma. Similarly, while just 52.38% of people gave Ambrx Biopharma an outstanding vote, 66.14% of users awarded Entera Bio an outperform rating.
With a beta of 1.34, AMAM stock price is 34% less volatile than that of the S&P 500. Compared to the S&P 500, Entera Bio's share price is 84% more unpredictable with a beta of 1.84. Ambrx Biopharma received 48 more media mentions than Entera Bio in the past week. Ambrx Biopharma received 49 mentions according to us, while Entera Bio received just one.
Shares Of Ambrx Rise After Promoting Early Safety
Preliminary safety and effectiveness findings from the Phase 2 ACE-Breast-03 study were released by Ambrx Biopharma Inc. (NASDAQ: AMAM), which encouraged early safety data from the breast cancer candidate.
In patients with HER2-positive mBC who are resistant or refractory to T-DM1, the data showed a 51.7% overall response rate (ORR) and a 100% disease control rate (DCR) after therapy with ARX788. Patients received therapy for a median of 7.2 months, as treatment is still ongoing.
In China, Amrbrx's partner NovoCodex Biopharmaceuticals is currently conducting two Phase 3 trials so one registration-enabled Phase 2 study with ARX788, with readouts expected in 2023. The last check Friday's premarket session saw AMAM shares up 180.6% to $1.15.
How Simple Is It For Ambrx Biopharma To Raise Money?
Many people may be thinking that Ambrx Biopharma has to raise more money in the future because its income is falling and its operating cash flow is rising. Companies have the option of raising capital through debt or equity.
Publicly traded corporations benefit greatly from the ability to sell investors shares in order to raise capital and finance expansion. By comparing a company's cash burn to its market capitalization, we may determine how much investors would be affected if the business had to issue capital to pay for the cash burn for an additional year.
Ambrx Biopharma seems to have a market value of $20 million and spent $7 million last year, or 350% of its market value. We believe there is a substantial risk of financial hardship given how big that expenditure is in comparison to the company's market value, and we would be extremely cautious about keeping the AMAM stock.
What Are The Average Rating And Price Objective For Ambrx Biopharma?
Based on the current 1 controlled transaction and 1 buy rating for AMAM, the consensus opinion for AMAM stock is Moderate Buy, according to the 2 analysts who have issued ratings in the past year. Ambrx Biopharma's average 12-month price objective is $4.00, with a premium price target of $4.00 and a low cost target of $4.00.
According to two Wall Street experts who have predicted the price of AMAM for the next year, the average price target is $11.00, with the maximum prediction for the company being $16.00 and the lowest prediction being $6.00.
By April 2023, according to the majority of Wall Street analysts, the share price of Ambrx Biopharma might be $11.00.
Is AMAM A Successful Business?
The cash burn for AMAM is $70163000. It has at least a year's worth of coverage in the form of cash and short-term investments. AMAM has cash and short-term investments of
$111.72 million. This is sufficient to fund its $70.16M yearly cash burn.
AMAM has a small 0.28 debt to equity ratio. On the balance sheet of AMAM, short-term assets outnumber long-term liabilities. On the balance sheet of AMAM, short-term assets exceed short-term liabilities. Cons: Over the past year, AMAM's profit margin has decreased from 325.6% to 1.729.9%.
According to our examination of Ambrx Biopharma's cash position, its cash runway was comforting, but the ratio of its cash burn to market value has us a little concerned. We have very little faith in the company's capacity to control its cash burn after taking all the data stated in this article into account, and we predict it will need additional money.
The Basics Of Ambrx Biopharma
The value of AMAM stock is 43, which is higher than the average for the Biotechnology sector. Currently, 3 out of 7 due diligence tasks are being passed by AMAM. AMAM's Financials rating is 0, which is the same as the industry average for the Biotechnology sector.
AMAM stock is presently failing 0 of 7 checks for due diligence. The AMAM stock forecast score is 0, which is the same as the sector average for biotechnology. AMAM stock is presently failing 0 of 9 checks for due diligence.
The Performance score for AMAM stock is 71, which is higher than the industry average for biotechnology. Five out of ten due diligence checks are passing for AMAM. We disregard this dimension because Ambrx Biopharma has little or no historical dividend history.
Recommendations Most Recent From AMAM Analysts
On May 24, 2022, a Goldman Sachs analyst decreases their price objective for AMAM stock from $6 to $4 while maintaining a hold rating.
On April 7, 2022, Joel Beatty, a high 17% analyst from Baird, commences covering on AMAM with a buy recommendation and publishes their $16.00 price target.
On February 28, 2022, Corinne Jenkins of Goldman Sachs, a top 48% analyst, announces the beginning of covering on AMAM with such a hold recommendation and a $6.00 price target.
In 2022, Should I Buy Or Sell Ambrx Biopharma Stock?
In the past year, Ambrx Biopharma has received "buy," "hold," and "sell" evaluations from 2 Wall Street research analysts. For the stock, there is presently 1 hold rating and 1 buy rating. Wall Street research experts generally agree that investors should "buy" AMAM stock. On Friday, June 18th 2021, (AMAM) raised $126 million through an initial public offering.
At a price of $17.00–$19.00 per share, the corporation issued 7,000,000 shares. The underwriters for the initial public offering were Goldman Sachs, BofA Securities, and Cowen. The time it would take for a corporation to exhaust its cash on hand at its current cash burn rate is known as its cash runway. Ambrx Biopharma had 111 million dollars in cash and no debt as of June 2022.
Looking back at the previous year, the business spent $70 million. So, starting in June 2022, AMAM stock forecast had a financial runway of about 19 months. This is not too bad, and unless cash burn substantially decreases, it is safe to assume the financial runway is coming to an end.
Ambrx Biopharma Stock Forecast 2022
While it is not anticipated that AMAM stock forecast annual earnings rate of growth of N/A will surpass the statistically important earnings growth rate of 9.29% for the US biotechnology industry, neither is it anticipated to surpass the average AMAM stock forecast earnings rate of growth of 70.08% for the US market.
The revenue for AMAM stock forecast in 2022 is -$90,558,000. One Wall Street analyst predicted that AMAM stock forecast earnings would be -$75,691,975 on average in 2022, with the highest AMAM earnings prediction being -$75,691,975 and the top AMAM stock forecast being -$75,691,975.
The current Earnings Per Share (EPS) for Ambrx Biopharma is $6.72. Analysts expect AMAM stock forecast EPS to be -$0.28 on average for 2022, with the lowest and highest estimates both coming in at -$0.28.
Ambrx Biopharma Stock Forecast
2023
AMAM stock forecast is anticipated to make -$67,582,121 in 2023, with the smallest earnings estimate being -$67,582,121 and the actual figure being -$67,582,121. By April 7, 2023, analysts on Wall Street believe the share price of Ambrx Biopharma might reach $11.00.
From the present share price of $4.54 for AMAM, the average AMAM stock forecast predicts a possible increase of 142.29%. AMAM stock forecast EPS is anticipated to be negative $0.25 in 2023.
0 notes
Text
Gastric Cancer Therapeutics Market Expected to Expand at a Steady 2021-2028 | Pfizer, Eli Lilly, GlaxoSmithKline
Gastric cancer, otherwise called stomach cancer, is a sort of cancer that creates inside within layer of the stomach. Manifestations might incorporate upper stomach torment, yellowing of the skin, indigestion, abrupt weight reduction, blood in the stool, loss of hunger, and queasiness, among others. This kind of cancer might duplicate to unaffected pieces of the body basically to the lungs, liver, the coating of the mid-region, lymph hubs, and bones. The critical reason for gastric cancer is a virus by Helicobacter pylori. This records around 60% of the gastric cancer cases. A few sorts of H. pylori contain bigger dangers than the others. A portion of different causes incorporate smoking and eating cured vegetables. Around 1 out of 10 instances of gastric cancer are acquired and 1% to 3% of the cases are because of genetic disorders like innate gastric cancer. Most instances of gastric cancers are gastric carcinomas.
Request Free Sample Copy With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/194
As indicated by World Cancer Research Fund International, 952,000 new instances of gastric cancer were analyzed in 2012. Gastric cancer was the fifth-most normal kind of cancer on the planet. This pandemic has constrained scientists, specialists, and states to embrace different helpful therapies identified with gastric cancer. An increment in the venture by the organizations and guidelines by the public authority empowering research on the equivalent has given critical force to the development of the gastric cancer therapeutics market. This pattern is probably going to continue all through the estimated time frame since the number of instances of gastric cancer throughout the planet is increasing at a disturbing rate.
As per National Cancer Institute, there were an extended 79,843 people with stomach cancer in the U.S. alone, in 2013. As indicated by a similar report, gastric cancer addressed an incredible 1.6% of the new cancer cases detailed in the U.S. As per the National Cancer Institute, an expected 26,370 new instances of the infection were accounted for, prompting 10,730 passings in the U.S. in 2016. The rising frequency of stomach cancer in the U.S. positions it as a high development market for gastric cancer therapeutics.
Expanding commonness of the illness in Asia to drive the development of generally gastric cancer therapeutics market
The endurance rate for stomach cancer is extraordinarily reliant upon the stage or period of the infection during the conclusion. The before the phase of the illness movement, the higher is the endurance rate. In the Asia Pacific, most of the cases are recognized at the later phase of the infection and dominate among the geriatric populace. The development of the geriatric populace in the area is prompting a corresponding expansion in event of gastric cancer. This component, alongside developing wellbeing mindfulness prompting an ascent in demand for early identification would fuel the development of the gastric cancer therapeutics industry over the conjecture time frame.
As of now, the items accessible in the market establish a broad assortment of treatment options like angiogenesis inhibitors, new chemotherapies, and HER2-designated treatment. In any case, the demand for therapeutics that can deal with HER2-negative stomach cancer patients is high. The gastric cancer market is encountering a slow change from nonexclusive therapy routines to designated treatments. This will additionally improve the development of the global gastric cancer therapeutics market.
Request PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/194
A portion of the organizations working in the gastric cancer therapeutics market in the current situation is F. Hoffmann-La Roche Ltd., Sanofi, Otsuka Holdings Co. Ltd., AstraZeneca, Merck KGaA, BMS, Kuhnil Pharmaceutical/Daiichi Sankyo, GlaxoSmithKline plc, Eli Lilly, and Pfizer. A portion of different organizations working in the market is Merck, Boston Biomedical, Celgene/Taiho, Gilead Bioscience, Jiangsu HengRui Medicine, Ono Pharmaceutical/Bristol-Myers Squibb.
Key Developments-
Central members in the market are centered around dispatching new items to expand their item portfolio. For example, in April 2019, F. Hoffmann-La Roche AG dispatched VENTANA HER2 Dual ISH DNA Probe Cocktail measure for the location of the HER2 biomarker in breast and gastric cancer.
Significant market players are centered around taking on joint effort procedures to foster novel treatments for gastric cancer. For example, in February 2019, GlaxoSmithKline plc. and Merck KGaA went into a global key partnership to together create and market M7824, an investigational bifunctional combination protein immunotherapy under clinical advancement stage, for the therapy of human papillomavirus-related cancers, biliary parcel cancer (BTC), and gastric cancer.
Key market players are likewise centered around acquiring administrative endorsements to expand their item portfolio. For instance, in August 2019, Taiho Pharmaceutical Co., Ltd. acquired an extra sign of unresectable progressed or intermittent gastric cancer that has advanced after chemotherapy for its anticancer specialist LONSURF, an oral anticancer medication that utilizes the mix of trifluridine (antineoplastic nucleoside simple) and tipiracil (a thymidine phosphorylase inhibitor), from the Japanese Ministry of Health, Labor and Welfare.
0 notes
Text
Increase in Awareness Regarding Cancer Treatment Expected to Drive Global Herceptin Biosimilar Market: Ken Research
Increase in Awareness Regarding Cancer Treatment Expected to Drive Global Herceptin Biosimilar Market: Ken Research
Herceptin is a specific type of monoclonal antibody, which is generally used to treat patients who are suffering from metastatic (spread) breast cancer & gastric cancers. It is also used as a part of the chemotherapy treatment for adjuvant-treatment of lymph-node positive, HER2/neu protein positive breast-cancer. Herceptin is also acknowledged as trastuzumab and primarily administered…
View On WordPress
#Global Herceptin Biosimilar Market Growth#Global Herceptin Biosimilar Market Trends#Mylan Herceptin Biosimilar Market Share
0 notes
Text
Cancer Biomarkers Market Status And Ongoing Development Trends Reviewed In New Report
The global cancer biomarkers market was valued at US$ xx million in the year 2019. This market is estimated to be valued at US$ xx million in the year 2020, and is expected to reach US$ xx million by the year 2025, with an estimated CAGR of 14.38% during the forecast period (2020−2025). Cancer biomarkers are biomolecules produced either by the tumor cells or by other cells of the body in reaction to the tumor. Biomarkers can be genes, gene products, specific cells, molecules, enzymes, or hormones which can be perceived in blood, urine, tissues, or other body fluid.
New product launches for cancer biomarkers is projected to boost growth of the market. For instance, in May 2019, Roche launched a new assay that can detect the Human Epidermal Growth Factor Receptor 2 (HER2) biomarker in breast and gastric cancer in the U.K. HER2 is an important biomarker found in breast and gastric cancers. This assay allows faster cancer detection.
Key Insights:
Latest Updates
Analyst Views
Future Outlook of the Market
Get Free PDF Brochure of this Report @ https://www.fostermarketresearch.com/product/industry/biotechnology/global-cancer-biomarkers-market/Pdf%20Brochure/
Competitive Landscape:
Key players in the global cancer biomarkers market include: Abbott Laboratories Inc., Agilent Technologies, 23andMe, Ambry Genetics, Biomerieux, Celera Corporation (Quest Diagnostics), F. Hoffmann-La Roche Ltd, Hologic Inc., Myriad Genetics, Inc., Bio-Rad Laboratories, Inc., bioMérieux, Inc., Creative Diagnostics, Illumina Inc., and Thermo Fisher Scientific among others.
Rise in reimbursement programs by government or key players is probable to enhance the market growth. For instance, in July 2018, German Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to evaluate the benefits and potential harm resulting from the use of biomarker-based tests to help doctors decide whether patients with primary breast cancer should receive adjuvant chemotherapy after surgery. Once feedbacks received, company is proposed to provide reimbursements for the biomarker products.
Market Taxonomy:
By Type
Genetic Biomarkers
Protein Biomarkers
Epigenetic Biomarkers
Metabolic Biomarkers
Others
By Cancer Type
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Others
By Application
Prognostics
Research and Development
Risk Assessment
Disease Diagnosis
By Profiling Technology
Immunoassay
Imaging Technology
Cytogenetics
OMICS Technology
Others
By End Users
Hospitals
Academic and Cancer Research Institutes
Diagnostic Laboratories
Ambulatory Surgical Centers
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Talk To Analyst @ https://www.fostermarketresearch.com/product/industry/biotechnology/global-cancer-biomarkers-market/Talk-to-Analyst/
Market Dynamics:
Rise in partnerships among the key players to obtain faster drug results is estimated to lift global cancer biomarkers market over the forecast period. For instance, in November 2018, Biocartis Group signed an agreement with AstraZeneca to receive faster lung cancer molecular diagnostic biomarker results in Europe. Under the agreement, both the companies collaborated to conduct prospective lung cancer study with Biocartis’s Idylla EGFR Mutation Test (CE-IVD) in more than 12 countries in Europe such as in Belgium, France, Germany and Italy.
However, product recalls by key players due to failure in working is projected to hinder the growth of global cancer biomarkers market during the forecast period. For instance, in October 2018, Ventana Medical Systems recalled FLO-LOK III Dispenser Detection kits due to leaking and sticking of reagent dispensers which could cause false negative results. FLO-LOK III Dispenser is used to indicate a disease state through the detection of biomarkers.
FAQ's:
Note: This report provides an in-depth analysis of the global cancer biomarkers market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2025), considering 2019, as the base year.
What are the trends adopted by key players in the global cancer biomarkers market?
What key factors are expected to increase the demand for global cancer biomarkers market during the forecast period 2020-2025?
What are the major challenges inhibiting the growth of the global cancer biomarkers market?
Which type (genetic biomarkers, protein biomarkers, epigenetic biomarkers, metabolic biomarkers, and others) is expected to dominate the global cancer biomarkers market in the coming years?
Which application (prognostics, research and development, risk assessment, and disease diagnosis) is expected to propel the market in the foreseen future?
Which profiling technology (immunoassay, imaging technology, cytogenetics, OMICS technology, and others) is expected to propel the market in the forecasted future?
What is the total market value (US$ Mn) generated in the global cancer biomarkers market by cancer type in 2019, and what are the forecasts by 2025?
Buy Now This Business Strategic Report to Improve Your Profits @ https://www.fostermarketresearch.com/product/buy/biotechnology/225/
About Foster Market Research:
Foster Market Research is a global market intelligence and advisory firm engaged in providing data-driven research extract from rigorous analysis, to the clients to make critical business decisions and execute them successfully. Foster connects over various distribution channels and numerous markets for great understanding of the trends and market to deliver our clients with accurate data.
Our focus is on providing market research that delivers a positive impact on your business. We work continuously to provide our clients with the most accurate analytics data and research reports without any delay so as to improve their business strategies and provide them with rich customer experience.
Contact Us:
1701 Royal Lane,
#1306, Dallas
Tx-75229
Phone: +1 469 4981929
Email: [email protected]
0 notes
Text
Global Gastric Cancer Drugs Market
Global Gastric Cancer Drugs Market Size, Share, Growth, Industry Trends and Forecast 2020-2030
Gastric cancer is the formation of abnormal cells on the inner lining of stomach resulting into stomach tumors. Additionally, Gastric cancer is also known as stomach cancer and gastric cancer drugs are used to treat malignancies or cancerous cells growth. The global gastric cancer drugs market accounted approximate USD 3.6 billion in 2020 and it is expected to reach USD 13.3 billion by 2030 with a CAGR of 13.80% during forecast period. According to report it is identified that gastric cancer was responsible for fourth most common malignancy occur in men and seventh rank in women. Additionally, treatment cancer is depends upon the stage of cancer and there are number of treatments available for the cancer such as chemo therapy, radiation therapy, surgery and others.
Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.decisionforesight.com/request-sample/DFS020190
Market Dynamics and Factors:
Rising incidence and prevalence rate of gastric cancer are boosting the global gastric cancer drugs market. Moreover, increasing in R&D studies and clinical trials to understand stomach cancer better and to develop medicine are highly contributing to the gastric cancer drugs market revenue. Additionally, increase in smoking population, obesity cases, consuming tobacco, unhealthy diet lifestyles resulting into the increase in number of cases in gastric cancer will drive the growth for gastric cancer drug market. However, high cost involved in the treatment and side effects due to prolonged use of cancer drugs hinders the growth of market. Moreover, the development of innovative drugs and rising awareness about these treatments among the consumers can be opportunity for the gastric cancer drugs market.
Market Segmentation:
Global Gastric Cancer Drugs Market – By Therapy Type
Kinase Inhibitors
Nucleoside Metabolic Inhibitors
Microtubule Inhibitors
VEGF Antibodies
Her2 Receptor Antagonists
Car T Cell Therapy
Global Gastric Cancer Drugs Market – By Route of Administration
Oral
Parenteral
Global Gastric Cancer Drugs Market – By Application
Adenocarcinomas
Gastrointestinal Stromal Tumors
Carcinoid Tumors
Global Gastric Cancer Drugs Market – By End-User
Hospital
Retail Pharmacy
Online Pharmacy
Global Gastric Cancer Drugs Market – By Geography
North America
U.S.
Canada
Mexico
Europe
U.K.
France
Germany
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia Pacific
ROW
Latin America
Middle East
Africa
New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC at @ https://www.decisionforesight.com/toc-request/DFS020190
Geographic Analysis:
North America is dominating the gastric cancer drugs market and is anticipated to maintain same trend during the forecast period. According to research study, guidelines of medicines regulatory agencies in the region are driving the market. Moreover, availability of better medical infrastructure, increase in R&D, availability of drug development therapies in the region driving the market for gastric cancer drugs. Asia Pacific is anticipated to witness fastest growth and is expected maintain same trend during forecast period. According, to research report the region generated approximate USD 1.12 billion revenue in 2018. Rise in incidences of gastric cancer in the region primarily in India and China are driving the growth of market. The World Health Organization (WHO) estimates that China accounted approximate 456,124 gastric cancer cases in 2018.
Competitive Scenario:
Some of the key players in global gastric cancer drugs market are F. Hoffmann-La Roche ltd., Novartis A.G., Eli Lily and company, Sanofi S.A., Bayer A.G., Otsuka pharmaceuticals co.Ltd., Gilead Sciences Inc., Celltrion Inc., Taiho pharmaceuticals co. ltd, and Merck & co. Inc.
Connect to Analyst @ https://www.decisionforesight.com/speak-analyst/DFS020190
How will this Market Intelligence Report Benefit You?
The report offers statistical data in terms of value (US$) as well as Volume (units) till 2030.
Exclusive insight into the key trends affecting the Global Gastric Cancer Drugs industry, although key threats, opportunities and disruptive technologies that could shape the Global Gastric Cancer Drugs Market supply and demand.
The report tracks the leading market players that will shape and impact the Global Gastric Cancer Drugs Market most.
The data analysis present in the Global Gastric Cancer Drugs Market report is based on the combination of both primary and secondary resources.
The report helps you to understand the real effects of key market drivers or retainers on Global Gastric Cancer Drugs Market business.
The 2021 Annual Global Gastric Cancer Drugs Market offers:
100+ charts exploring and analysing the Global Gastric Cancer Drugs Market from critical angles including retail forecasts, consumer demand, production and more
15+ profiles of top producing states, with highlights of market conditions and retail trends
Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand
Benchmark wholesale prices, market position, plus prices for raw materials involved in Global Gastric Cancer Drugs Market type
Buy This Premium Research Report@ https://www.decisionforesight.com/checkout/DFS020190
About Us:
Decision Foresight is a market research organization known for its reliable and genuine content, market estimation and the best analysis which is designed to deliver state-of-the-art quality syndicate reports to our customers. Apart from syndicate reports, you will find the best market insights, strategies that will help in taking better business decisions on subjects that may require you to develop and grow your business-like health, science, technology and many more. At Decision Foresight, we truly believe in disseminating the right piece of knowledge to a large section of the audience and cover the in-depth insights of market leaders across various verticals and horizontals.
Contact:
Email: [email protected]
For Latest Update Follow Us:
https://www.facebook.com/Decision-Foresight-110793387201935
https://twitter.com/DecisionFs
https://www.linkedin.com/company/decision-foresight/
0 notes
Photo
Ambrx gets orphan drug designation for gastric cancer treatment ARX788 #gastriccancer “The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive gastric cancer. The Office of Orphan Drug Products of the FDA grants such orphan status to aid the development of medicines for underprivileged patients, or rare disorders, affecting less than 200,000 people in the US. With the orphan drug designation for ARX788 to treat patients with gastric cancer and cancer at the gastroesophageal junction, biopharmaceutical company Ambrx – which creates engineered precision biologics with the aid of an expanded genetic code – gets to enjoy benefits such as exemption towards tax credits for qualified clinical trials and FDA prescription drug user fees. The designation also makes Ambrx eligible for 7 years of market exclusivity to an orphan drug post-approval, after Ambrx receives a marketing approval from the FDA.” #MSL #FSTP #MSLcert #medicalscienceliaison medical science liaison #Medicalaffairs https://www.instagram.com/p/CMtCordj0dc/?igshid=pfjafxulo4hx
0 notes
Text
Incyte makes bid to join the checkpoint inhibitor club
Incyte has filed its PD-1 inhibitor retifanlimab with the FDA, seeking approval to treat a form of anal cancer associated with human papillomavirus (HPV) and HIV infections.
The application covers the use of the intravenous PD-1 inhibitor for adults with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy, and an FDA decision is due by 25 July after a priority, six-month review.
If approved, retifanlimab (formerly INCMGA0012) would be the first PD-1/PD-L1 checkpoint inhibitor to be approved for SCAC, providing Incyte with a niche indication to grow the drug without competition.
That will be important, as retifanlimab is in line to be the seventh or eighth drug in the class to reach the market, coming after a roll call of big pharma oncology giants. It may get the nod before GlaxoSmithKline’s dostarlimab, also under review at the FDA for endometrial cancer.
Incyte’s drug is following in the footsteps of Merck & Co’s Keytruda (pembrolizumab), Bristol-Myers Squibb’s Opdivo (nivolumab), Roche’s Tecentriq (atezolizumab), AstraZeneca’s Imfinzi (durvalumab), Pfizer/Merck KgAA’s Bavencio (avelumab) and Sanofi’s Libtayo (cemiplimab), which collectively have dozens of approved uses.
Cases of SCAC have been on the rise in recent decades, but it is still relatively uncommon, accounting for about 4% of all anorectal tumours, according to a 2020 review paper.
In Europe, rates range from around 1 to 3 cases per 100,000 people, while in the US there were about 8,200 new cases of SCAC recorded in 2017. The FDA has granted orphan drug status to retifanlimab as that makes it a rare disease.
While survival rates for SCAC have increased thanks to refinements to first-line chemotherapy, patients with SCAC that has spread around the body have a poor chance of living beyond five years.
At the moment, there are no FDA-approved treatments for patients who have progressed after first-line chemo for this “historically neglected, yet important, tumour,” according to Icyte’s head of immuno-oncology Lance Leopold.
“Despite SCAC being a rare disease, its incidence is increasing and its impact is profound,” he added.
Incyte’s marketing application is based on the phase 2 POD1UM-202 trial reported at last year’s ESMO cancer congress, which found an objective response rate of 14% for retifanlimab, regardless of the tumour’s PD-L1 expression, whether it had spread to the liver, or the patient’s age or HIV status.
SCAC may be free of competition for Incyte’s drug, but the company’s development plan includes other indications that will put it in contention with the checkpoint inhibitor heavyweights.
It is in trials alongside chemotherapy in previously-untreated non-small cell lung cancer (NSCLC) – dominated at the moment by Keytruda – and SCAC, and as a monotherapy for microsatellite instability (MSI) high endometrial cancer and Merkel cell carcinoma.
Retifanlimab was originally developed by MacroGenics and licensed to Incyte in 2017 for $150 million upfront and up to $750 million in development and commercial milestones.
MacroGenics said in November it had claimed $25 million so far in milestone payments triggered by clinical and regulatory activities including the start of POD1UM-303, a phase 3 trial in SCAC.
Analysts don’t expect big sales from retifanlimab on its own – maybe in the ballpark of $500 million – but there could be upsides if the drug proves its value in combination with other therapies.
Those include a mid-stage study with MacroGenics’ margetuximab in HER2-positive gastric cancer that the partners think could lead to regulatory filings if the results are positive.
The post Incyte makes bid to join the checkpoint inhibitor club appeared first on .
from https://pharmaphorum.com/news/incyte-makes-bid-to-join-the-checkpoint-inhibitor-club/
0 notes
Text
Lifescience Reagent Market Insights
Increasing prevalence of infectious disease, which requires early diagnosis is creating the opportunity for the biotechnology industry players to produce effective reagents to carry out various diagnostic tests. Moreover, launching of new diagnostic tests and assays is contributing to the lifescience reagents market share. For instance, in April 2019, Roche launched Ventana HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer patients to determine the eligibility for the targeted drug trastuzumab (Herceptin). The new reagent is intended for in vitro diagnostic (IVD) use.
The global lifescience reagent market was valued at US$ 33,754.0 million in 2017, and is expected to witness a CAGR of 7.3% during the forecast period (2018–2026).
Figure 1. Global Lifescience Reagent Market value Analysis (US$ Mn) and Forecast and Absolute $ Opportunity
Source: Coherent Market Insights Analysis (2019)
Increasing number of product launches is expected to drive growth of global lifescience reagent market
Increasing product launches for reagents to assist different types of diagnostics tests and research purpose is expected to drive the global lifescience reagent market growth. For instance, in March 2019, Dolomite Bio, a provider of single cell technologies, launched a new scRNA-Seq reagent kit to expand the Nadia Instrument portfolio. The new scRNA-Seq reagent kit is designed to enable the generation of PCRamplified cDNA libraries on the Nadia Instrument, allowing high throughput gene expression profiling of heterogeneous cell populations.
Moreover, in October 2016, Beckman Coulter’s lifescience division launched Clearllab LS Lymphoid Screen Reagent. It is CE-marked and 10-colour containing 12 antibody reagent combinations used for leukemia and lymphoma analysis. The new approach is designed to provide results with a faster turnaround time (TAT). ClearLLab has been specifically designed for identification of haematolymphoid cells on the Beckman Coulter’s Navios flow cytometer.
Increasing acquisitions among biotechnology industry players is contributing to the global lifescience reagent market during the forecast period. For instance, in February 2017, Anatrace (StoneCalibre’s portfolio company), acquired Molecular Dimensions Ltd. Molecular Dimensions Ltd is the U.K.-based supplier of modern screens, reagents, and other consumables and instrumentation for structural biology research. With this acquisition, Anatrace intended to establish its presence in Europe and expand its position in the structural biology product portfolio.
Global Lifescience Reagent Market- Regional Analysis
North America is expected to witness lucrative growth in global lifescience reagent market, owing to growing initiatives taken by market players to establish their product portfolio in North American countries. For instance, in May 2018, Grifols received the U.S. Food & Drug Administration (FDA) licensing approval to commercialize a range of antisera reagents designed for routine and complex immunohematology testing in the U.S.
Moreover, in 2016, LabX Media Group, Inc. acquired 1DegreeBio Inc., (www.1degreebio.com), the antibody and reagent search engine for lifesciences. With this acquisition, LabX Media Group introduced 1DegreeBio Inc. to its portfolio of established brands. The website ‘www.1degreebio.com’ includes a database of lifescience reagents and kits including quality validation data, citation history, as well as antibody reviews and community ratings.
Asia Pacific is also expected to drive the global lifescience reagent market growth, owing to presence of key players in this regions. For instance, in December 2015, Sekisui Chemical, a Japanese company, acquired Eidia, a subsidiary company of Eisai, to develop and market reagents, especially diagnostic reagents, for curbing cancer and rheumatism. Eisai was the manufacturer, importer, and marketer of chemical equipment, clinical diagnostic reagents, clinical analyzers, and laboratory reagents. Sekisui purchased the Eidia from Eisai for US$ 18 million.
Europe is expected to show significant lifescience reagent growth rate, owing to increasing number of approvals from the European Union for the diagnostics reagents and assays. For instance, in March 2017, HTG Molecular Diagnostics, Inc. received CE marking in the European Union for its HTG EdgeSeq ALKPlus Assay EU. The company is provider of instruments, reagents, and services for molecular profiling applications. HTG EdgeSeq ALKPlus Assay EU is an in vitro diagnostic assay used to measure and analyze mRNA ALK gene rearrangements in formalin-fixed, paraffin-embedded lung tumor specimens from patients previously diagnosed with non-small cell lung cancer (NSCLC).
Figure 2: Global Lifescience Reagent Market Value (US$ Mn), By Region
Source: Coherent Market Insights Analysis (2019)
Global Lifescience Reagent Market - Competitive Landscape
Key players operating in the global lifescience reagent market include F. Hoffmann-La Roche Ltd., Danaher Corporation, Abbott Laboratories, Merck KGaA, Bio-Rad Laboratories, GE Healthcare, Siemens Healthineers, Becton, Dickinson and Company, Agilent Technologies Inc., Perkin Elmer Inc., Waters Corporation, Ortho Clinical Diagnostics, bioMérieux SA, and Sysmex Corporation.
Buy now the market research report here:
https://www.coherentmarketinsights.com/insight/buy-now/2681
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis
Request the sample copy of here:
https://www.coherentmarketinsights.com/insight/request-sample/2681
Download the PDF Brochure here:
https://www.coherentmarketinsights.com/insight/request-pdf/2681
Explore CMI Services here
Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email: [email protected]
Source:
https://www.coherentmarketinsights.com/market-insight/lifescience-reagent-market-2681
0 notes
Text
Using its unique expanded genetic code technology platform, Ambrx Biopharma Inc.(AMAM stock) , a clinical-stage biologics firm, discovers and creates tailored precision biologics. Its lead product candidate, ARX788, is an anti-HER2-drug conjugate (ADC) that is being studied in numerous clinical trials to treat of breast cancer, stomach junction cancer, as well as other solid tumors. These trials, which are currently in Phase 2 and Phase 3, are also being conducted for the treatment of gastric and breast cancers that have metastasized and are HER2-positive.
The company is also working on two earlier-stage product candidates: ARX305, an anti-CD70 ADC in investigational new chemical studies for the treatment of kidney cell carcinoma and other cancers. And ARX517, an anti-PSMA ADC in a Phase 1 clinical trial for the therapy of prostate cancer and other tumors.
It is also creating additional multiple product candidates with an eye toward immuno-oncology applications, such as ARX102, an immuno-oncology IL-2 path agonist that targets and gamma receptors on cytotoxic T cells to activate the patient's own immune system, and ARX822, a fab-small macromolecular bispecific that is used in preclinical phase for cancers. Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health are all partners of Ambrx Biopharma Inc. The business was founded in 2003, and its main office is in La Jolla, California.
Who Are The Major Owners Of AMAM Stock?
17 investment banks and fund managers owned AMAM stock in Ambrx Biopharma over the previous two years. Fosun International Ltd ($37.88M), Adage Capital Partners GP L.L.C. ($17.37M), BlackRock Inc. ($11.75M), FMR LLC ($10.22M), Octagon Capital Advisors LP ($8.82M), Suvretta Capital Management LLC ($6.15M), and Millennium Management LLC ($2.82M) were the institutional investors with the largest investments.
AMAM stock is held by institutions 44.21% of the time. In the past 24 months, institutional investors have purchased 9,197,182 shares altogether. This volume of purchases entails about $158.86M in transactions.
In the past 24 months, investment banks have sold 274,909 shares in total. This share sale volume equates to roughly $1.55M in business. Institutional shareholders Cormorant Asset Management LP ($0.15M), BlackRock Inc. ($48.46K), Tudor Investment Corp Et Al ($39.86K), Ghisallo Capital Management LLC ($25K), and Renaissance Technologies LLC ($11.60K) all sold shares of Ambrx Biopharma in the past 24 months.
Short Sellers Of Ambrx Biopharma?
November saw a decrease in short interest in Ambrx Biopharma. 3,800 shares totaled short interest as of November 15th, which is a decrease of 20.8% from the 4,800 share total as of October 31st. The days-to-cover ratio is currently 0.1 days based on an average daily trading volume of 30,600 shares.
Short sales of the company's shares make up about 0.0% of the total. Any online trading account can be used to buy shares of AMAM stock. WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab are a few well-known online brokerages providing access to the American stock market.
Competitors Of AMAM
The top rivals of Ambrx Biopharma include Elevation Oncology (ELEV), Cortexyme, Idera Pharmaceuticals (IDRA), Rubius Therapeutics (RUBY), Jasper Therapeutics (JSPR), Entera Bio (ENTX), AIM ImmunoTech (AIM), ERYTECH Pharma (ERYP), Genetic Technologies (GENE), Surrozen (SRZN), and (CRTX).
All of these businesses fall under the "medical" category. Ambrx Biopharma is not as well-liked by analysts as other Medical companies. AMAM stock has a consensus rating of Moderate Buy, whereas the typical consensus rating for healthcare firms is Buy.
Ambrx Biopharma is disliked by customers more than other Medical businesses. Ambrx Biopharma had an outperform vote from 52.38% of people, versus an average of 66.26% for medical firms.
Entera Bio And Ambrx Biopha
rma?
Compared to Ambrx Biopharma, Entera Bio has smaller revenue but larger earnings. Shares in Ambrx Biopharma are held by institutions 44.2% of the time. Comparatively, institutional investors own 17.1% of the shares in Entera Bio. Shares of Ambrx Biopharma are held by company insiders to a 5.1% stake. Comparatively, insiders own 5.2% of the shares in Entera Bio. Solid organizational ownership is a sign that endowments, hedge funds, and big money managers are betting on a company's long-term ability to outperform the market.
Compared to Entera Bio's profit income of -1,796.49%, Ambrx Biopharma has a net margin of 0.00%. Entera Bio's return on equity was beaten by Ambrx Biopharma's equity return of 0.00%. When compared by users, Entera Bio earned 157 more votes for outperformance than Ambrx Biopharma. Similarly, while just 52.38% of people gave Ambrx Biopharma an outstanding vote, 66.14% of users awarded Entera Bio an outperform rating.
With a beta of 1.34, AMAM stock price is 34% less volatile than that of the S&P 500. Compared to the S&P 500, Entera Bio's share price is 84% more unpredictable with a beta of 1.84. Ambrx Biopharma received 48 more media mentions than Entera Bio in the past week. Ambrx Biopharma received 49 mentions according to us, while Entera Bio received just one.
Shares Of Ambrx Rise After Promoting Early Safety
Preliminary safety and effectiveness findings from the Phase 2 ACE-Breast-03 study were released by Ambrx Biopharma Inc. (NASDAQ: AMAM), which encouraged early safety data from the breast cancer candidate.
In patients with HER2-positive mBC who are resistant or refractory to T-DM1, the data showed a 51.7% overall response rate (ORR) and a 100% disease control rate (DCR) after therapy with ARX788. Patients received therapy for a median of 7.2 months, as treatment is still ongoing.
In China, Amrbrx's partner NovoCodex Biopharmaceuticals is currently conducting two Phase 3 trials so one registration-enabled Phase 2 study with ARX788, with readouts expected in 2023. The last check Friday's premarket session saw AMAM shares up 180.6% to $1.15.
How Simple Is It For Ambrx Biopharma To Raise Money?
Many people may be thinking that Ambrx Biopharma has to raise more money in the future because its income is falling and its operating cash flow is rising. Companies have the option of raising capital through debt or equity.
Publicly traded corporations benefit greatly from the ability to sell investors shares in order to raise capital and finance expansion. By comparing a company's cash burn to its market capitalization, we may determine how much investors would be affected if the business had to issue capital to pay for the cash burn for an additional year.
Ambrx Biopharma seems to have a market value of $20 million and spent $7 million last year, or 350% of its market value. We believe there is a substantial risk of financial hardship given how big that expenditure is in comparison to the company's market value, and we would be extremely cautious about keeping the AMAM stock.
What Are The Average Rating And Price Objective For Ambrx Biopharma?
Based on the current 1 controlled transaction and 1 buy rating for AMAM, the consensus opinion for AMAM stock is Moderate Buy, according to the 2 analysts who have issued ratings in the past year. Ambrx Biopharma's average 12-month price objective is $4.00, with a premium price target of $4.00 and a low cost target of $4.00.
According to two Wall Street experts who have predicted the price of AMAM for the next year, the average price target is $11.00, with the maximum prediction for the company being $16.00 and the lowest prediction being $6.00.
By April 2023, according to the majority of Wall Street analysts, the share price of Ambrx Biopharma might be $11.00.
Is AMAM A Successful Business?
The cash burn for AMAM is $70163000. It has at least a year's worth of coverage in the form of cash and short-term investments. AMAM has cash and short-term investments of
$111.72 million. This is sufficient to fund its $70.16M yearly cash burn.
AMAM has a small 0.28 debt to equity ratio. On the balance sheet of AMAM, short-term assets outnumber long-term liabilities. On the balance sheet of AMAM, short-term assets exceed short-term liabilities. Cons: Over the past year, AMAM's profit margin has decreased from 325.6% to 1.729.9%.
According to our examination of Ambrx Biopharma's cash position, its cash runway was comforting, but the ratio of its cash burn to market value has us a little concerned. We have very little faith in the company's capacity to control its cash burn after taking all the data stated in this article into account, and we predict it will need additional money.
The Basics Of Ambrx Biopharma
The value of AMAM stock is 43, which is higher than the average for the Biotechnology sector. Currently, 3 out of 7 due diligence tasks are being passed by AMAM. AMAM's Financials rating is 0, which is the same as the industry average for the Biotechnology sector.
AMAM stock is presently failing 0 of 7 checks for due diligence. The AMAM stock forecast score is 0, which is the same as the sector average for biotechnology. AMAM stock is presently failing 0 of 9 checks for due diligence.
The Performance score for AMAM stock is 71, which is higher than the industry average for biotechnology. Five out of ten due diligence checks are passing for AMAM. We disregard this dimension because Ambrx Biopharma has little or no historical dividend history.
Recommendations Most Recent From AMAM Analysts
On May 24, 2022, a Goldman Sachs analyst decreases their price objective for AMAM stock from $6 to $4 while maintaining a hold rating.
On April 7, 2022, Joel Beatty, a high 17% analyst from Baird, commences covering on AMAM with a buy recommendation and publishes their $16.00 price target.
On February 28, 2022, Corinne Jenkins of Goldman Sachs, a top 48% analyst, announces the beginning of covering on AMAM with such a hold recommendation and a $6.00 price target.
In 2022, Should I Buy Or Sell Ambrx Biopharma Stock?
In the past year, Ambrx Biopharma has received "buy," "hold," and "sell" evaluations from 2 Wall Street research analysts. For the stock, there is presently 1 hold rating and 1 buy rating. Wall Street research experts generally agree that investors should "buy" AMAM stock. On Friday, June 18th 2021, (AMAM) raised $126 million through an initial public offering.
At a price of $17.00–$19.00 per share, the corporation issued 7,000,000 shares. The underwriters for the initial public offering were Goldman Sachs, BofA Securities, and Cowen. The time it would take for a corporation to exhaust its cash on hand at its current cash burn rate is known as its cash runway. Ambrx Biopharma had 111 million dollars in cash and no debt as of June 2022.
Looking back at the previous year, the business spent $70 million. So, starting in June 2022, AMAM stock forecast had a financial runway of about 19 months. This is not too bad, and unless cash burn substantially decreases, it is safe to assume the financial runway is coming to an end.
Ambrx Biopharma Stock Forecast 2022
While it is not anticipated that AMAM stock forecast annual earnings rate of growth of N/A will surpass the statistically important earnings growth rate of 9.29% for the US biotechnology industry, neither is it anticipated to surpass the average AMAM stock forecast earnings rate of growth of 70.08% for the US market.
The revenue for AMAM stock forecast in 2022 is -$90,558,000. One Wall Street analyst predicted that AMAM stock forecast earnings would be -$75,691,975 on average in 2022, with the highest AMAM earnings prediction being -$75,691,975 and the top AMAM stock forecast being -$75,691,975.
The current Earnings Per Share (EPS) for Ambrx Biopharma is $6.72. Analysts expect AMAM stock forecast EPS to be -$0.28 on average for 2022, with the lowest and highest estimates both coming in at -$0.28.
Ambrx Biopharma Stock Forecast
2023
AMAM stock forecast is anticipated to make -$67,582,121 in 2023, with the smallest earnings estimate being -$67,582,121 and the actual figure being -$67,582,121. By April 7, 2023, analysts on Wall Street believe the share price of Ambrx Biopharma might reach $11.00.
From the present share price of $4.54 for AMAM, the average AMAM stock forecast predicts a possible increase of 142.29%. AMAM stock forecast EPS is anticipated to be negative $0.25 in 2023.
0 notes
Text
Using its unique expanded genetic code technology platform, Ambrx Biopharma Inc.(AMAM stock) , a clinical-stage biologics firm, discovers and creates tailored precision biologics. Its lead product candidate, ARX788, is an anti-HER2-drug conjugate (ADC) that is being studied in numerous clinical trials to treat of breast cancer, stomach junction cancer, as well as other solid tumors. These trials, which are currently in Phase 2 and Phase 3, are also being conducted for the treatment of gastric and breast cancers that have metastasized and are HER2-positive.
The company is also working on two earlier-stage product candidates: ARX305, an anti-CD70 ADC in investigational new chemical studies for the treatment of kidney cell carcinoma and other cancers. And ARX517, an anti-PSMA ADC in a Phase 1 clinical trial for the therapy of prostate cancer and other tumors.
It is also creating additional multiple product candidates with an eye toward immuno-oncology applications, such as ARX102, an immuno-oncology IL-2 path agonist that targets and gamma receptors on cytotoxic T cells to activate the patient's own immune system, and ARX822, a fab-small macromolecular bispecific that is used in preclinical phase for cancers. Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health are all partners of Ambrx Biopharma Inc. The business was founded in 2003, and its main office is in La Jolla, California.
Who Are The Major Owners Of AMAM Stock?
17 investment banks and fund managers owned AMAM stock in Ambrx Biopharma over the previous two years. Fosun International Ltd ($37.88M), Adage Capital Partners GP L.L.C. ($17.37M), BlackRock Inc. ($11.75M), FMR LLC ($10.22M), Octagon Capital Advisors LP ($8.82M), Suvretta Capital Management LLC ($6.15M), and Millennium Management LLC ($2.82M) were the institutional investors with the largest investments.
AMAM stock is held by institutions 44.21% of the time. In the past 24 months, institutional investors have purchased 9,197,182 shares altogether. This volume of purchases entails about $158.86M in transactions.
In the past 24 months, investment banks have sold 274,909 shares in total. This share sale volume equates to roughly $1.55M in business. Institutional shareholders Cormorant Asset Management LP ($0.15M), BlackRock Inc. ($48.46K), Tudor Investment Corp Et Al ($39.86K), Ghisallo Capital Management LLC ($25K), and Renaissance Technologies LLC ($11.60K) all sold shares of Ambrx Biopharma in the past 24 months.
Short Sellers Of Ambrx Biopharma?
November saw a decrease in short interest in Ambrx Biopharma. 3,800 shares totaled short interest as of November 15th, which is a decrease of 20.8% from the 4,800 share total as of October 31st. The days-to-cover ratio is currently 0.1 days based on an average daily trading volume of 30,600 shares.
Short sales of the company's shares make up about 0.0% of the total. Any online trading account can be used to buy shares of AMAM stock. WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab are a few well-known online brokerages providing access to the American stock market.
Competitors Of AMAM
The top rivals of Ambrx Biopharma include Elevation Oncology (ELEV), Cortexyme, Idera Pharmaceuticals (IDRA), Rubius Therapeutics (RUBY), Jasper Therapeutics (JSPR), Entera Bio (ENTX), AIM ImmunoTech (AIM), ERYTECH Pharma (ERYP), Genetic Technologies (GENE), Surrozen (SRZN), and (CRTX).
All of these businesses fall under the "medical" category. Ambrx Biopharma is not as well-liked by analysts as other Medical companies. AMAM stock has a consensus rating of Moderate Buy, whereas the typical consensus rating for healthcare firms is Buy.
Ambrx Biopharma is disliked by customers more than other Medical businesses. Ambrx Biopharma had an outperform vote from 52.38% of people, versus an average of 66.26% for medical firms.
Entera Bio And Ambrx Biopha
rma?
Compared to Ambrx Biopharma, Entera Bio has smaller revenue but larger earnings. Shares in Ambrx Biopharma are held by institutions 44.2% of the time. Comparatively, institutional investors own 17.1% of the shares in Entera Bio. Shares of Ambrx Biopharma are held by company insiders to a 5.1% stake. Comparatively, insiders own 5.2% of the shares in Entera Bio. Solid organizational ownership is a sign that endowments, hedge funds, and big money managers are betting on a company's long-term ability to outperform the market.
Compared to Entera Bio's profit income of -1,796.49%, Ambrx Biopharma has a net margin of 0.00%. Entera Bio's return on equity was beaten by Ambrx Biopharma's equity return of 0.00%. When compared by users, Entera Bio earned 157 more votes for outperformance than Ambrx Biopharma. Similarly, while just 52.38% of people gave Ambrx Biopharma an outstanding vote, 66.14% of users awarded Entera Bio an outperform rating.
With a beta of 1.34, AMAM stock price is 34% less volatile than that of the S&P 500. Compared to the S&P 500, Entera Bio's share price is 84% more unpredictable with a beta of 1.84. Ambrx Biopharma received 48 more media mentions than Entera Bio in the past week. Ambrx Biopharma received 49 mentions according to us, while Entera Bio received just one.
Shares Of Ambrx Rise After Promoting Early Safety
Preliminary safety and effectiveness findings from the Phase 2 ACE-Breast-03 study were released by Ambrx Biopharma Inc. (NASDAQ: AMAM), which encouraged early safety data from the breast cancer candidate.
In patients with HER2-positive mBC who are resistant or refractory to T-DM1, the data showed a 51.7% overall response rate (ORR) and a 100% disease control rate (DCR) after therapy with ARX788. Patients received therapy for a median of 7.2 months, as treatment is still ongoing.
In China, Amrbrx's partner NovoCodex Biopharmaceuticals is currently conducting two Phase 3 trials so one registration-enabled Phase 2 study with ARX788, with readouts expected in 2023. The last check Friday's premarket session saw AMAM shares up 180.6% to $1.15.
How Simple Is It For Ambrx Biopharma To Raise Money?
Many people may be thinking that Ambrx Biopharma has to raise more money in the future because its income is falling and its operating cash flow is rising. Companies have the option of raising capital through debt or equity.
Publicly traded corporations benefit greatly from the ability to sell investors shares in order to raise capital and finance expansion. By comparing a company's cash burn to its market capitalization, we may determine how much investors would be affected if the business had to issue capital to pay for the cash burn for an additional year.
Ambrx Biopharma seems to have a market value of $20 million and spent $7 million last year, or 350% of its market value. We believe there is a substantial risk of financial hardship given how big that expenditure is in comparison to the company's market value, and we would be extremely cautious about keeping the AMAM stock.
What Are The Average Rating And Price Objective For Ambrx Biopharma?
Based on the current 1 controlled transaction and 1 buy rating for AMAM, the consensus opinion for AMAM stock is Moderate Buy, according to the 2 analysts who have issued ratings in the past year. Ambrx Biopharma's average 12-month price objective is $4.00, with a premium price target of $4.00 and a low cost target of $4.00.
According to two Wall Street experts who have predicted the price of AMAM for the next year, the average price target is $11.00, with the maximum prediction for the company being $16.00 and the lowest prediction being $6.00.
By April 2023, according to the majority of Wall Street analysts, the share price of Ambrx Biopharma might be $11.00.
Is AMAM A Successful Business?
The cash burn for AMAM is $70163000. It has at least a year's worth of coverage in the form of cash and short-term investments. AMAM has cash and short-term investments of
$111.72 million. This is sufficient to fund its $70.16M yearly cash burn.
AMAM has a small 0.28 debt to equity ratio. On the balance sheet of AMAM, short-term assets outnumber long-term liabilities. On the balance sheet of AMAM, short-term assets exceed short-term liabilities. Cons: Over the past year, AMAM's profit margin has decreased from 325.6% to 1.729.9%.
According to our examination of Ambrx Biopharma's cash position, its cash runway was comforting, but the ratio of its cash burn to market value has us a little concerned. We have very little faith in the company's capacity to control its cash burn after taking all the data stated in this article into account, and we predict it will need additional money.
The Basics Of Ambrx Biopharma
The value of AMAM stock is 43, which is higher than the average for the Biotechnology sector. Currently, 3 out of 7 due diligence tasks are being passed by AMAM. AMAM's Financials rating is 0, which is the same as the industry average for the Biotechnology sector.
AMAM stock is presently failing 0 of 7 checks for due diligence. The AMAM stock forecast score is 0, which is the same as the sector average for biotechnology. AMAM stock is presently failing 0 of 9 checks for due diligence.
The Performance score for AMAM stock is 71, which is higher than the industry average for biotechnology. Five out of ten due diligence checks are passing for AMAM. We disregard this dimension because Ambrx Biopharma has little or no historical dividend history.
Recommendations Most Recent From AMAM Analysts
On May 24, 2022, a Goldman Sachs analyst decreases their price objective for AMAM stock from $6 to $4 while maintaining a hold rating.
On April 7, 2022, Joel Beatty, a high 17% analyst from Baird, commences covering on AMAM with a buy recommendation and publishes their $16.00 price target.
On February 28, 2022, Corinne Jenkins of Goldman Sachs, a top 48% analyst, announces the beginning of covering on AMAM with such a hold recommendation and a $6.00 price target.
In 2022, Should I Buy Or Sell Ambrx Biopharma Stock?
In the past year, Ambrx Biopharma has received "buy," "hold," and "sell" evaluations from 2 Wall Street research analysts. For the stock, there is presently 1 hold rating and 1 buy rating. Wall Street research experts generally agree that investors should "buy" AMAM stock. On Friday, June 18th 2021, (AMAM) raised $126 million through an initial public offering.
At a price of $17.00–$19.00 per share, the corporation issued 7,000,000 shares. The underwriters for the initial public offering were Goldman Sachs, BofA Securities, and Cowen. The time it would take for a corporation to exhaust its cash on hand at its current cash burn rate is known as its cash runway. Ambrx Biopharma had 111 million dollars in cash and no debt as of June 2022.
Looking back at the previous year, the business spent $70 million. So, starting in June 2022, AMAM stock forecast had a financial runway of about 19 months. This is not too bad, and unless cash burn substantially decreases, it is safe to assume the financial runway is coming to an end.
Ambrx Biopharma Stock Forecast 2022
While it is not anticipated that AMAM stock forecast annual earnings rate of growth of N/A will surpass the statistically important earnings growth rate of 9.29% for the US biotechnology industry, neither is it anticipated to surpass the average AMAM stock forecast earnings rate of growth of 70.08% for the US market.
The revenue for AMAM stock forecast in 2022 is -$90,558,000. One Wall Street analyst predicted that AMAM stock forecast earnings would be -$75,691,975 on average in 2022, with the highest AMAM earnings prediction being -$75,691,975 and the top AMAM stock forecast being -$75,691,975.
The current Earnings Per Share (EPS) for Ambrx Biopharma is $6.72. Analysts expect AMAM stock forecast EPS to be -$0.28 on average for 2022, with the lowest and highest estimates both coming in at -$0.28.
Ambrx Biopharma Stock Forecast
2023
AMAM stock forecast is anticipated to make -$67,582,121 in 2023, with the smallest earnings estimate being -$67,582,121 and the actual figure being -$67,582,121. By April 7, 2023, analysts on Wall Street believe the share price of Ambrx Biopharma might reach $11.00.
From the present share price of $4.54 for AMAM, the average AMAM stock forecast predicts a possible increase of 142.29%. AMAM stock forecast EPS is anticipated to be negative $0.25 in 2023.
0 notes
Last Seen Blogs
hotfromaroundtumbler
porninoneplace
callpisces43
The Life of Munch 530
goreboys-inc
GOREBOYS INCORPORATED!
my-love-perfect
Lismar
vie-transitoire
tragédias